A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

September 13, 2019

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
MigraineMajor Depressive Disorder
Interventions
DRUG

Fremanezumab

Monthly 225 mg subcutaneous

DRUG

Placebo

Matching Placebo

Trial Locations (64)

10461

Teva Investigational Site 14345, The Bronx

11229

Teva Investigational Site 14335, Brooklyn

11528

Teva Investigational Site 63075, Athens

15125

Teva Investigational Site 63077, Marousi

19107

Teva Investigational Site 14338, Philadelphia

20100

Teva Investigational Site 40055, Turku

20132

Teva Investigational Site 30237, Milan

21018

Teva Investigational Site 58320, Vinnytsia

21208

Teva Investigational Site 14336, Pikesville

26655

Teva Investigational Site 32733, Westerstede

27100

Teva Investigational Site 30235, Pavia

32256

Teva Investigational Site 14334, Jacksonville

32801

Teva Investigational Site 14341, Orlando

33012

Teva Investigational Site 14329, Hialeah

33100

Teva Investigational Site 40056, Tampere

33634

Teva Investigational Site 14411, Tampa

37203

Teva Investigational Site 14339, Nashville

38119

Teva Investigational Site 14333, Memphis

41013

Teva Investigational Site 31276, Seville

42277

Teva Investigational Site 35267, Saint-Priest-en-Jarez

45133

Teva Investigational Site 32737, Essen

45147

Teva Investigational Site 32731, Essen

46026

Teva Investigational Site 31274, Valencia

47003

Teva Investigational Site 31272, Valladolid

50009

Teva Investigational Site 31273, Zaragoza

50134

Teva Investigational Site 30236, Florence

65613

Teva Investigational Site 14343, Bolivar

69500

Teva Investigational Site 35265, Bron

70600

Teva Investigational Site 40058, Kuopio

72205

Teva Investigational Site 14330, Little Rock

80218

Teva Investigational Site 14342, Denver

88100

Teva Investigational Site 30242, Catanzaro

90220

Teva Investigational Site 40057, Oulu

92103

Teva Investigational Site 14337, San Diego

97214

Teva Investigational Site 14340, Portland

119021

Teva Investigational Site 50482, Moscow

121467

Teva Investigational Site 50483, Moscow

129128

Teva Investigational Site 50480, Moscow

603137

Teva Investigational Site 50481, Nizhny Novgorod

650000

Teva Investigational Site 58321, Odesa

3810101

Teva Investigational Site 80172, Hadera

4941492

Teva Investigational Site 80178, Petah Tikva

5822012

Teva Investigational Site 80173, Holon

7661041

Teva Investigational Site 80175, Rehovot

9112001

Teva Investigational Site 80177, Jerusalem

06905

Teva Investigational Site 14332, Stamford

02451

Teva Investigational Site 14331, Waltham

565 01

Teva Investigational Site 54190, Choceň

140 59

Teva Investigational Site 54183, Prague

160 00

Teva Investigational Site 54184, Prague

186 00

Teva Investigational Site 54185, Prague

516 01

Teva Investigational Site 54186, Rychnov nad Kněžnou

01307

Teva Investigational Site 32736, Dresden

04275

Teva Investigational Site 32734, Leipzig

09648

Teva Investigational Site 32732, Mittweida

166 75

Teva Investigational Site 63076, Glyfada

00128

Teva Investigational Site 30232, Roma

00163

Teva Investigational Site 30234, Rome

30-539

Teva Investigational Site 53447, Krakow

60-529

Teva Investigational Site 53445, Poznan

01-737

Teva Investigational Site 53446, Warsaw

52-416

Teva Investigational Site 53448, Wroclaw

04080

Teva Investigational Site 58319, Kiyv

SE1 7EH

Teva Investigational Site 34254, London

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT04041284 - A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter